Good MorningEquities closed the week higher but on shaky footing following a pivot from the FOMC. Fed Chief Jerome Powell indicated the committee could slow the pace of interest rate hikes as soon as the next meeting which was what the market wanted to hear. The bad news is that inflation, labor and wage data does not support the idea that inflation is under control or that the Fed can ease off on its policy. While the committee may slow to a 50 basis point pace it should also be expected to continue hiking at that pace until inflation is indeed at 2.0%.
This week could be dicey for traders due to a lack of data on both economics and earnings. There are few notable reports due out but they are interesting on an individual basis only and unlikely to alter the big picture in any way. The takeaway is that conditions are still changing an not for the better. While labor markets remain strong and underpinned by rising wages the impact on consumer spending is getting worse at the same time. The risk is that, at some point, the scale will tip and consumer spending will contract in a meaningful way and bring the economy down with it. Featured: President Trump ordered this to happen… (Ad) 
|
Technology | | Customer relationship management software giant Salesforce (NASDAQ: CRM) shares tanked (-10%) on a bullish Q3 2022 earnings report but Q4 guidance was mixed. The Company beat analyst expectations as shares initially popped but then sank upon the announcement that Salesforce Co-CEO Bret Taylor would ... Read the Full Story |
|
From Our Partners | | CFA and CMT analyst Garrett Goggin called G2 Goldfields before it rose 1,023%, Reunion Gold before 538%, Highlander Silver before 741%, and Orogen Royalty before 416%. He also publicly predicted Newmont's 126% gain in 2025.
Now Goggin says the 1974 petrodollar agreement between Washington and Riyadh has quietly expired, central banks are buying gold at the fastest pace since 1950, and a major monetary shift is underway. He has identified four specific positions - plus two bonus opportunities for readers. | | Read the full briefing and see all four positions plus two bonuses |
|
Technology | | U.S. semiconductor producer Intel (NASDAQ: INTC) stock is trading at price levels not seen since 2016. While shares rallied after a strong earnings report, the guidance was exceptionally weak, but shares have managed to grind higher despite the warnings. The markets may have finally started to belie... Read the Full Story |
|
Medical | | Approaching the final week of November CSL Ltd ADR (OTCMKTS: CSLLY) received some good news as the United States Food and Drug Administration approved CSL Behring's new gene therapy drug, HEMEGENIX (etranacogene dezaparvovec-drib) for treating hemophilia B. The news helped continue the stock's upwar... Read the Full Story |
|
From Our Partners | | 17,556% on KDA. Here's what I'm buying now.
It's a coin under $1.00 that most investors have never heard of. But the world's largest bank is already building on it. It has a deflationary burn mechanism tied directly to institutional usage. | | Click to see my #1 pick. |
|
Technology | |
After releasing an earnings report that beat analyst estimates, Okta Inc (NASDAQ: OKTA) share value shot up significantly. While not all the data was impressive, share volume still cranked up to 20.30 million—more than six times the OTKA average daily volume—to help boost the value fro... Read the Full Story |
|
Technology | |
Ambarella (NASDAQ: AMBA) shares are down more than 65% from their post-pandemic highs and may move lower. The Q4 results were good but guidance is on the weak side. That may weigh on share prices, but that's a good thing. Ambarella stock is up off of its recent lows and at a high 68x valuation, so... Read the Full Story |
|
From Our Partners | | Looking for better stock ideas? Sign-up to receive The Early Bird Stock of the Day. Each day, MarketBeat's team of expert research analysts identifies one compelling stock and provides both a bull case and a bear case for each company. | | Get The Early Bird's Stock of the Day (Free) |
|
Transportation | | ZIM Integrated Shipping Services (NYSE: ZIM) offers an example of what’s befallen the once red-hot shipping industry in the past six months. The Israel-based company’s stock is down 33.58% in the past three months and down 17.48% year-to-date.
Its wider industry has suffered a similar f... Read the Full Story |
|
Basic Materials | |
Put simply, dividends are the primary method by which a publicly traded company returns profits to shareholders.
Are you ready to understand “What is a good dividend yield?” in simple terms? You may also want to simplify your knowledge of what a dividend is and why you might want to ... Read the Full Story |
|
Auto/Tires/Trucks | |
Although EV startups such as NIO (NYSE: NIO) and Mullen Automotive (NASDAQ: MULN) are grabbing attention, along with 800-pound gorilla Tesla (NASDAQ: TSLA), long-established automakers such as Ford (NYSE: F) and General Motors (NYSE: GM) are quickly ramping up EV production and marketing.
Ford sa... Read the Full Story |
|
Auto/Tires/Trucks | | To say the short sellers were wrong about Mullen Automotive (NASDAQ: MULN) would be ludicrous. With the stock down 95% in the last year alone, it is obvious the short sellers were very, very right about Mullen Automotive stock.
Are they right now? The company has issued many positive news releases... Read the Full Story |
|
Consumer Discretionary | |
La-Z-Boy (NYSE: LZB) shares are reclining into a more comfortable price range following the Q2 earnings release and guidance but this is an opportunity for investors. The decline in share prices is driven by a cautious outlook for the 3rd quarter that does little to offset the value, quality or yi... Read the Full Story |
|
Monday's Early Bird Stock Of The Day Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland. | | View Today's Stock Pick |
|
